Background Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …

In this study, a method was developed for the efficient entrapment of active tissue-type
Plasminogen Activator (t-PA) into liposomes. Experimental conditions were varied to …

Although nanotechnology has shown great promise for treating multiple vascular diseases
in recent years, simultaneous noninvasive detection and efficient dissolution of deep venous …

Eptifibatide is an antiplatelet drug used for the treatment of thrombosis. However, as a result
of its accumulation in non-targeted tissues and short half-life, it has a limited efficacy. In this …

Thrombotic diseases have a high rate of mortality and disability, and pose a serious threat to
global public health. Currently, most thrombolytic drugs especially protein drugs have a …

Currently available anti-thrombotic therapy for the prophylaxis and treatment of arterial and
venous thrombosis includes intravenous administration of anti-thrombotic drugs which lead …

The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …

Neutrophil extracellular traps (NETs) play a crucial role in the formation of vulnerable
plaques and the development of atherosclerosis. Alleviating the pathological process of …

Manufacturing of liposomal nanomedicines (eg Doxil®/Caelyx®) is a challenging and slow
process based on multiple-vessel and batch processing techniques. As a result, the …

The successful design of new thrombolytic agents depends on providing these agents with
increased clot selectivity. As recently demonstrated (10), entrapment of tissue plasminogen …